Real‐World Outcomes of Telemedicine Shared Medical Appointments in Obesity Management Authors: Keerthana Haridas, Jeffrey Wei, Lei Lei, Derek Pham, Nicholas Jackson, Na Shen Published: 2026 ABSTRACT ABSTRACTIntroductionShared Medical Appointments (SMAs) have recently emerged as a novel tool in weight management as they are efficient, bypass logistic barriers to physical attendance, decrease attrition, and are cost‐effective. This study aimed to observe outcomes among patients enrolled in an insurance‐based weight loss program, called Program for Reducing Obesity (PRO), utilizing telemedicine SMAs during a 12 month period of chronic weight management.MethodsPatients of age ≥ 18 years with BMI ≥ 30 kg/m2 were enrolled in the program, consisting of telemedicine SMAs with an obesity medicine board‐certified physician and a registered dietitian. The primary outcome was the change in body weight at 6 and 12 months. Secondary outcomes were changes in glycated hemoglobin (HgbA1c) and triglyceride (TG) levels.ResultsOne hundred and nine patients, who had been enrolled in the program for about 18 months, were included in the study. The mean age was 62.40 ± 12.5 years. 73% were treated with obesity management medications. Patients attended an average of 10 classes through SMAs. 51% of patients had prediabetes, and 25% had Type 2 Diabetes Mellitus (DM). The mean weight of patients at baseline was 97.54 ± 19 kg, with an average weight loss of 2.38 ± 4.78 kg (2.43%) and 4.47 ± 7.77 kg (4.55%) at 6 and 12 months (p < 0.001). The mean baseline HgbA1c and TG levels were 5.96 ± 0.8% and 137.43 ± 112.4 mg/dL, respectively. HgbA1c levels decreased by 0.11 ± 0.65 (2.19%) and 0.20 ± 0.50 (3.70%) at 6 and 12 months, and TG levels decreased by 25.19 ± 104.60 mg/dL (33.60%) at 6 months and 35.83 ± 112.08 mg/dL (41.14%) at 12 months (p < 0.05). There were no statistically significant differences in weight loss between sexes, and regardless of the presence of DM, use of obesity management medications, or the number of classes attended.ConclusionThis study showed that telemedicine SMAs are an effective and efficient method for promoting weight loss, even in the ongoing maintenance phase. Introduction Current strategies for weight management include lifestyle modification, obesity management medications, and metabolic and bariatric surgery (MBS). However, these treatment options are all grossly underutilized. For instance, weight loss counseling occurred in fewer than 6% of primary care visits in 2003–2004; [1] only 0.8% of eligible patients received obesity management medication between 2015 and 2018 [2], and merely 1% of eligible patients underwent metabolic and bariatric surgery in 2018 [3]. There also exists a significant amount of weight bias, both explicit and implicit, among healthcare providers, which further hampers utilization of weight management by patients. Use of inappropriate language, implied associations of overweight and obesity with lack of intelligence and motivation, as well as increased perceived non‐adherence to both lifestyle and pharmacologic recommendations, are some manifestations of this bias [4, 5, 6, 7]. Endocrinologists often receive referrals for the evaluation and management of obesity‐related comorbidities such as diabetes mellitus (DM), hypertension, and polycystic ovary syndrome. They are well situated to help with obesity management. They are also aware of the genetic and syndromic causes of obesity. The engagement of endocrinologists and other physicians certified in obesity management will likely improve the delivery of lifestyle counseling in conjunction with the utilization of obesity management medication (OMM) and MBS. However, increased demand for these providers leading to limited access, lengthy wait times for appointments, and lack of adequate insurance coverage continue to pose challenges in this model of weight management [8, 9]. In recent years, shared medical appointments (SMA) have emerged as a new platform for the delivery of weight management. SMAs allow patients to convene in a group setting with a team of multidisciplinary healthcare providers for education, counseling, and individualized care [10]. SMAs improve obesity care management through accessibility, accountability, peer support, as well as enhanced cost and time effectiveness [10, 11]. Literature on the utilization of SMAs in obesity management is sparse, but a few studies have demonstrated that participants in SMA weight management programs were more likely to receive obesity management medication [12] and sustain significant weight loss for up to 9, 12, or 24 months [10, 11, 12, 13]. Most recently, the Program for Reducing Obesity (PRO) published a single‐arm study following 102 patients initiated into an in‐person version of the SMA program, showing that over half of the participants lost at least 5% of baseline weight by 12 months, consistent with prior studies [14]. 5% weight reduction is considered clinically significant as it is associated with reduced risk of progression to type 2 DM, hepatic steatosis, and improvement in glycemic control, systolic blood pressure, triglyceride (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol levels in all patients, and increased ovulation frequency, and fertility in patients with polycystic ovary syndrome [15]. The COVID‐19 pandemic posed challenges to the traditional in‐person care model and created fertile ground for the widespread adoption of telemedicine. Telemedicine encompasses the use of communication tools such as text messages, phone calls, videoconferences, multimedia educational materials, and remote health monitoring devices [16, 17]. Advantages of telemedicine pertinent to obesity management include improved access to trained health care providers for underserved populations, cost reduction, and better long‐term adherence through decreased time and resource barriers for patients [17]. A recent meta‐analysis of 16 curated randomized controlled trials involving 1875 participants showed a significant mean difference of 0.93 (confidence interval 0.58–1.28) favoring the use of telemedicine in obesity management in US adults over 40 years old [18]. Given the advantages of SMA and telemedicine, weight loss programs incorporating SMA classes using a telemedicine platform have the potential to meet the growing need for obesity care and reach a broader patient base, although their efficacy has not been extensively studied. Previous studies showed that patients newly enrolled in telemedicine SMA programs achieved between 3.5% and 6.4% weight loss after 11–16 weeks, and the magnitude of weight loss was similar to that noted in those who received in‐person care [19, 20, 21, 22]. Shared decision making is a guideline endorsed cornerstone of obesity management due to the current availability of varying medical and surgical options for long‐term weight management, each with its own efficacy, side effect profile, affordability, and access barriers. The patient's comorbidities, goals, preferences, and prior experiences shape this decision, in conjunction with the provider's recommendations. Shared medical appointments, allowing simultaneous engagement of patients with multiple providers across disciplines, facilitate close supervision and dynamic modification of treatment plans adjusted to patients' progress, goals and response. A recent multilevel trial in two health systems aimed at increasing the use of shared decision making (SDM) in MBS found that providers and other stakeholders experienced multiple key barriers to SDM, including a lack of structural prioritization of SDM, time constraints, and reimbursement issues [23]. Sub‐optimal patient‐provider communication has also been highlighted as an important cause of underutilization of MBS [24]. The SMA model, by virtue of its structure, can embed SDM into its workflow, unify organizational incentives with improved patient care and free up provider time and cognitive bandwidth for deep DSM, thus overcoming many, if not all of these barriers [25]. Despite their advantages, particularly in a field that incorporates information dissemination as part of intensive lifestyle counseling, the utilization of SMAs remains low, although few studies have examined this in detail. A national survey in 2022 found that SMAs were among the least adopted patient care models among other engagement strategies [26]. A study by the Cleveland Clinic, where annual SMA visits increased from 385 visits approximately 2002 and 2004 to 12,300 visits in 2017, highlights inadequate physical and staffing resources, including technology, patient recruitment challenges, and lack of insurance coverage as barriers to wider utilization [27]. A systematic review explored 18 studies incorporating SMA use and reported that administrative challenges, unclear expectations of roles of different team members, and lack of structured leadership were challenges to higher uptake [28]. To add to the growing literature of telemedicine SMA in obesity management, particularly in the ongoing chronic phase, data on the metabolic impact of telemedicine SMAs through the Program for Reducing Obesity is made available. Materials and Methods Study Design and Population Patients aged ≥ 18 years with body mass index (BMI) ≥ 30 kg/m2 were eligible by referral from their primary care provider or endocrinologist to the program starting in January 2019, with the inclusion of telemedicine SMA appointments beginning in March 2020. There were no other explicit exclusion criteria. The Program for Reducing Obesity is an institutional, insurance‐based program consisting of shared medical appointments (SMA) with an obesity medicine board‐certified physician and registered dietitian. A detailed description of the program can be found in a previous publication [14]. Data from 109 patients who received care exclusively using telemedicine between October 2023 and October 2024 were analyzed. The patients were already enrolled in the program and had been receiving care for an average of around 1.5 years, albeit with possible interruptions and pauses in receiving care. Patients referred to the program initially met for a one‐on‐one 40‐min visit with an obesity medicine board‐certified physician who introduced them to the program, gathered pertinent past medical history, assessed risk factors for obesity and its comorbidities, obtained body composition data if able to arrange an in‐person visit, formulated a nutrition and exercise plan, and completed a workup for secondary causes of obesity if indicated. These patients were then referred to the weekly telemedicine SMA visits, where they received individual medical counseling, including pharmacotherapy modification from the physician, and lifestyle didactics and counseling from the dietitian in the form of group classes. They followed a nutritionally balanced, portion‐controlled diet, individualized to promote weight loss. These visits occurred at a minimum after 1, 3, 6 and 12 months following the initial visit. Measures Primary outcomes were absolute and percentage change in body weight after 6 and 12 months during the study period. Secondary outcomes included changes in hemoglobin (HgbA1c) and TG levels. Because of the telemedicine nature of the appointments, insufficient data were obtained to examine changes in body composition as measured by the Tanita segmental body composition analyzer during in‐person visits. Additional information, including date of enrollment in the program, patient sex, race/ethnicity, history of metabolic and bariatric surgery, history of diabetes mellitus or prediabetes, use of OM, and number of classes attended, was collected. Obesity management medications included the following: phentermine, topiramate, phentermine‐topiramate, naltrexone‐bupropion, glucagon‐like peptide 1‐ receptor agonists (GLP1RA) including semaglutide, dulaglutide, and liraglutide, as well as dual Glucagon‐Like Peptide‐1 (GLP‐1) and Glucose‐Dependent Insulinotropic Polypeptide (GIP) agonist tirzepatide. Statistical Analysis Descriptives for all variables were generated and assessed for normality. Absolute and percentage changes in each variable relative to baseline were calculated for 6 and 12 months. Changes from baseline were assessed using mixed effect linear regression (absolute change) and generalized mixed effect models with logarithmic linkage (relative change). Models were fitted using a subject random intercept with a fixed effect for time period (baseline, 6 months, 12 months) modeled as a categorical factor. Tests for differential change over time as a function of sex, diabetes diagnosis, use of OM, and number of sessions attended were examined by incorporating these variables as main effects and interaction with the time period fixed effect. Statistical significance was determined using a two‐sided alpha of 0.05. All statistical analyses were performed using R version (4.4.2) and Stata MP version 18 (Stata Corp LLC, College Station, Texas). Results Study Participants One hundred and nine patients participated in the study. Demographics and baseline characteristics are shown in Table 1. Eighty‐one (81) percent of patients identified as women, and 73% were on OMM either as monotherapy or combination therapy. OMMs were chosen based on body weight, co‐morbidities, adverse effect profile, and insurance coverage. Table 2 shows the distribution of OMM among patients. Five patients had previously undergone MBS. The mean age of the patients was 62.4 + 12.5 years. Patients attended an average of 10 classes through SMAs. Sixty‐four percent (64%) of patients attended 5 or more classes. The mean weight of patients at baseline was 97.54 ± 19 kg. Fifty‐one percent (51%) of patients had prediabetes, and 25% had Type 2 Diabetes Mellitus. The mean baseline HgbA1c and TG levels were 5.96 ± 0.8% and 137.43 ± 112.4 mg/dL, respectively. TABLE 1Demographic characteristics of patients.Demographic characteristics N = 109Age, Mean ± SD62.4 ± 12.5Sex, N (%)Female88 (81%)Male21 (19%)Diabetes diagnosis, N (%)Nil25 (23%)Prediabetes56 (51%)T1DM1 (1%)T2DM27 (25%)Number of classes, Mean ± SD10.4 ± 10.1Attended ≥ 5 classes, N (%)70 (64%)Used obesity medications, N (%)79 (73%)Has been on GLP1RA/GIP, N (%)67 (61%)Baseline weight kg (lbs), Mean ± SD97.54 ± 19 (215 ± 42)Baseline HgbA1c, Mean ± SD5.96 ± 0.80BF%, Mean ± SD44.3 ± 6.4Baseline triglycerides (mg/dL), Mean ± SD137.43 ± 112.4 Demographic characteristics of patients. TABLE 2Obesity management medication use.MedicationNumber of patientsTirzepatide (Zepbound/Mounjaro)14Semaglutide (Wegovy/Ozempic/Rybelsus)49Dulaglutide1Liraglutide1Phentermine—topiramate5Phentermine16Topiramate3 Obesity management medication use. Primary Outcomes Primary outcomes are reported in Table 3. All patients had already been initiated on diet and lifestyle modification, with or without the use of OMM, for an average of 17.8 months during the time of this study (median duration of 15 months of being enrolled in the program). They had already lost an average of 6.9 ± 8.9 kg. Patients continued to achieve statistically significant weight loss during the time of this study: 2.38% (2.38 ± 4.78 kg/), 4.55% (4.47 ± 7.77 kg/) of their weight at 6‐month, and 12‐month follow‐up (p‐values < 0.001 for all comparisons). Figure 1 shows the percent weight change from baseline of each patient. The percentage weight change at 12 months ranged from −25.20% to +9.91%. TABLE 3Changes in body weight, HgbA1c, and TG among patients.OutcomeDescriptive statisticsAbsolute change from baselinePercent change from baseline N Mean ± SDMean change ± SD p Mean % change ± SD p Weight Kg(lbs)Baseline109 a 97.54 ± 18.91 (215.04 ± 41.69)RefRef6 months102 a 94.26 ± 18.14 (207.80 ± 39.99) −2.38 ± 4.78 (−5.25 ± 10.53) < 0.001−2.38% ± 4.48%< 0.00112 months104 a 93.06 ± 18.11 205.17 ± 39.93 −4.47 ± 7.77 (−9.85 ± 17.13) < 0.001−4.55% ± 4.48%< 0.001HgbA1cBaseline86 a 5.96 ± 0.80RefRef6 months70 a 5.97 ± 0.57−0.11 ± 0.650.11−2.19% ± 6.52%0.04612 months78 a 5.80 ± 0.56−0.20 ± 0.500.002−3.70% ± 6.52%0.001TG (mg/dL)Baseline86 a 137.43 ± 112.36RefRef6 months68 a 116.65 ± 48.23−25.19 ± 104.600.016−33.60% ± 37.61%< 0.00112 months70 a 100.71 ± 46.10−35.83 ± 112.08< 0.001−41.14% ± 37.61%< 0.001 a Sample size with data at these time points. Full sample size (Weight N = 109; HgbA1c N = 99; TG N = 94) used in the mixed effect models. Changes in body weight, HgbA1c, and TG among patients. −2.38 ± 4.78 (−5.25 ± 10.53) −4.47 ± 7.77 (−9.85 ± 17.13) Sample size with data at these time points. Full sample size (Weight N = 109; HgbA1c N = 99; TG N = 94) used in the mixed effect models. Percent change in body weight among patients. Changes from baseline were assessed using mixed effect linear regression (absolute change) and generalized mixed effect regression with logarithmic linkage (relative change). Secondary Outcomes Secondary outcomes are reported in Table 3. A subset of patients had data on HgbA1c (N = 99) and TG (N = 94) at one of the 3 time points. HgbA1c decreased by 0.11 ± 0.65 (2.19%) and 0.20 ± 0.50 (3.70%) from baseline at 6 and 12 months, respectively, though the absolute change at 6 months was not reliably different from baseline (p = 0.11). TG levels among these patients decreased by 25.19 ± 104.60 mg/dL (33.60%) and 35.83 ± 112.08 mg/dL (41.14%) from baseline at 6 and 12 months, respectively. Tests for Differential Change by Sex, Diabetes Status, OM Use and Number of Classes Attended Tests for differences in change over time by sex, diabetes status (Type 1 diabetes mellitus & type 2 diabetes mellitus vs. pre‐diabetes & nil), OMM use, and number of classes attended (≥ 5 vs. < 5) are presented in Table 4. TABLE 4Differential change over time in weight, HgbA1c, and TG by Sex, diabetes status, number of classes attended, and anti‐obesity medication (OM).Absolute change at 6 monthsAbsolute change at 12 monthsPercent change at 6 monthsPercent change at 12 monthsΔ (95% CI) p Δ (95% CI) p Δ (95% CI) p Δ (95% CI) p Weight (kg)Female−2.33 (−3.62, −1.03)< 0.001−4.35 (−5.64, −3.06)< 0.001−2.32% (−3.65%, −0.96%)< 0.001−4.54% (−5.86%, −3.21%)< 0.001Male−2.71 (−5.40, −0.02)0.048−5.13 (−7.77, −2.49)< 0.001−2.57% (−4.95%, −0.14%)0.038−4.53% (−6.80%, −2.21%)< 0.001 p‐interaction0.800.600.850.99No diabetes−2.54 (−3.88, −1.19)< 0.001−4.65 (−6.00, −3.31)< 0.001−2.57% (−3.92%, −1.20%)< 0.001−4.83% (−6.16%, −3.48%)< 0.001Diabetes−1.98 (−4.33, 0.37)0.099−4.05 (−6.33, −1.76)< 0.001−1.82% (−4.10%, 0.51%)0.124−3.76% (−5.94%, −1.53%)0.001 p‐interaction0.690.650.580.41< 5 classes−1.60 (−3.63, 0.43)0.121−3.45 (−5.41, −1.48)< 0.001−1.59% (−3.64%, 0.50%)0.135−3.42% (−5.34%, −1.46%)< 0.001≥ 5 classes−2.83 (−4.25, −1.41)< 0.001−5.08 (−6.51, −3.65)< 0.001−2.80% (−4.20%, −1.37%)< 0.001−5.16% (−6.56%, −3.75%)< 0.001 p‐interaction0.330.190.340.15No OMM−2.32 (−4.64, −0.00)0.049−3.12 (−5.44, −0.80)0.008−2.10% (−4.32%, 0.17%)0.07−3.07% (−5.28%, −0.81%)0.008Yes OMM−2.42 (−3.79, −1.05)< 0.001−5.08 (−6.44, −3.72)< 0.001−2.46% (−3.85%, −1.06%)< 0.001−5.16% (−6.49%, −3.80%)< 0.001 p‐interaction0.940.150.790.12HgbA1cFemale−0.13 (−0.28, 0.01)0.068−0.13 (−0.27, 0.00)0.057−2.64% (−4.92%, −0.30%)0.026−2.39% (−4.57%, −0.16%)0.035Male−0.05 (−0.34, 0.23)0.723−0.48 (−0.76, −0.19)0.001−1.47% (−5.74%, 3.00%)0.512−8.30% (−12.43%, −3.98%)< 0.001 p‐interaction0.610.0320.640.016No diabetes0.03 (−0.12, 0.18)0.70−0.07 (−0.21, 0.07)0.297−0.54% (−3.09%, 1.95%)0.674−1.26% (−3.61%, 1.13%)0.298Diabetes−0.48 (−0.71, −0.25)< 0.001−0.57 (−0.80, −0.35)< 0.001−7.46% (−10.52%, −4.31%)< 0.001−8.77% (−11.78%, −5.65%)< 0.001 p‐interaction< 0.001< 0.001< 0.001< 0.001< 5 classes−0.18 (−0.42, 0.06)0.134−0.27 (−0.50, −0.05)0.018−3.76% (−7.42%, 0.06%)0.052−4.92% (−8.45%, −1.25%)0.008≥ 5 classes−0.07 (−0.23, 0.09)0.366−0.16 (−0.31, −0.01)0.038−1.49% (−4.03%, 1.11%)0.258−3.01% (−5.43%, −0.52%)0.017 p‐interaction0.470.420.330.39No OM−0.10 (−0.35, 0.16)0.47−0.09 (−0.33, 0.15)0.47−1.67% (−5.71%, 2.55%)0.43−1.47% (−5.33%, 2.56%)0.47Yes OM−0.11 (−0.27, 0.04)0.16−0.24 (−0.39, −0.09)0.001−2.42% (−4.88%, 0.11%)0.06−4.44% (−6.80%, −2.03%)< 0.001 p‐interaction0.910.300.760.20TGFemale−14.52 (−36.24, 7.20)0.19−19.66 (−40.80, 1.49)0.068−15.02% (−24.70%, −4.09%)0.007−17.74% (−27.32%, −6.88%)0.001Male−76.29 (−121.50, −31.07)< 0.001−113.44 (−159.91, −66.97)< 0.001−58.51% (−65.49%, −50.11%)< 0.001−71.63% (−78.28%, −62.96%)< 0.001 p‐interaction0.015< 0.001< 0.001< 0.001No diabetes−24.94 (−48.98, −0.90)0.042−34.46 (−57.15, −11.78)0.002−37.74% (−47.26%, −26.52%)< 0.001−44.61% (−53.56%, −33.93%)< 0.001Diabetes−29.20 (−68.43, 10.04)0.144−40.00 (−83.65, 3.65)0.072−26.89% (−40.05%, −10.84%)0.002−33.59% (−47.94%, −15.28%)< 0.001 p‐interaction0.860.830.220.24< 5 classes−45.12 (−82.63, −7.62)0.018−47.61 (−85.25, −9.98)0.013−58.30% (−66.97%, −47.37%)< 0.001−65.57% (−74.37%, −53.74%)< 0.001≥ 5 classes−17.07 (−41.80, 7.66)0.176−31.79 (−55.93, −7.65)0.009−20.42% (−30.36%, −9.05%)< 0.001−29.64% (−39.21%, −18.57%)< 0.001 p‐interaction0.220.49< 0.001< 0.001No OM−21.61 (−63.98, 20.75)0.32−31.43 (−71.17, 8.32)0.12−30.55% (−46.27%, −10.24%)0.003−35.61% (−49.76%, −17.46%)< 0.001Yes OM−26.55 (−50.81, −2.29)0.031−38.34 (−62.38, −14.30)0.001−35.33% (−44.48%, −24.68%)< 0.001−44.39% (−53.60%, −33.35%)< 0.001 p‐interaction0.840.770.640.35 Differential change over time in weight, HgbA1c, and TG by Sex, diabetes status, number of classes attended, and anti‐obesity medication (OM). No statistically significant difference was noted in weight loss between sexes, between patients with and without DM, status of OMM use, or number of classes attended (≥ 5 vs. < 5). Most patients chose not to disclose their races/ethnicities, thus, weight loss differences among different races/ethnicities could not be obtained. For HgbA1c, men demonstrated larger statistically significant decreases in absolute (Δ−0.48 vs. −Δ0.13, p = 0.032) and relative glycated hemoglobin (Δ−8.30% vs. Δ−2.39%, p = 0.016) at 12 months but not at 6 months. Individuals with diabetes mellitus were more likely to have greater absolute and relative decreases in HgbA1c at both 6 months (−0.48 [−7.46%] vs. 0.03 [0.54%], p < 0.001) and 12 months (−0.57 [−8.77%] vs. −0.07 [−1.26%], p < 0.001). There were no reliable differences in changes in HgbA1c from baseline based on the number of classes attended or OMM use. For TG levels, men had greater absolute and relative decreases from baseline at both 6 months (−76.29 mg/dL [−58.51%] vs. −14.52 mg/dL [−15.02%], p < 0.05) and 12 months (−113.44 [−71.63%] vs. −19.66 [−17.74%], p < 0.001). There were no reliable differences in TG change from baseline between those with and without diabetes mellitus or OMM use. For class attendance, those who attended 5 or more classes showed less of a decrease in relative TG levels at 6 months (−20.42% vs. −58.30%, p < 0.001) and 12 months (−29.64% vs. −65.57%, p < 0.001) compared to those who attended < 5 classes. There were no reliable differences in absolute TG levels. Discussion This study indicates that the program facilitated further weight loss among individuals who were likely to encounter a plateau in weight loss at the time of the study, and supports a growing body of literature on the use of telemedicine in weight management. The results from this study compare with the results from Azar et al.’s [19] virtual small groups, delivering material adapted from the Diabetes Prevention Program (DPP) and Brown et al.’s rural multidisciplinary behavioral weight program [20]. Both studies utilized videoconferencing group sessions in a primary care setting [19, 20]. Das et al. examining a commercial weight loss program, showed a weight loss of 6.1 ± 3.9% with no significant difference between videoconference versus in‐person groups after 11 weeks [22]. In a noninferiority study using a 16 week lifestyle intervention program based on the DPP, the videoconference‐only cohort lost 6.8% of their baseline weight, comparable to 7.6% weight loss in the combined face‐to‐face and videoconference cohort [29]. Similarly, a 12 week retrospective study, comparing a virtual versus in‐person multidisciplinary intensive lifestyle intervention, showed weight loss of 7.4 and 6.8 kg, respectively [30]. Several longer‐term studies also demonstrate the efficacy of telemedicine interventions. Clark et al. found that 34% of participants in the videoconferencing intervention group achieved at least 2 kg weight loss by 12 months, similar to 29% in the community in‐person group and the enhanced usual care group [31]. Befort et al. found no significant difference in weight loss between participants receiving telephone group visits and in‐clinic individual visits by 24 months, with weight loss of 3.9 and 2.6 kg, respectively [32]. A review of 7 studies by Ufholz and Bhargava in 2021 showed statistically significant changes in diet, physical activity, and weight/body fat changes among participants who engaged in telemedicine models of weight management [33]. The SMA model has proven efficacy in weight management. Results from individual studies showed that SMAs can produce significant weight loss among adult patients. Shibuya et al. showed higher weight loss in the group that utilized SMAs as opposed to the group that did not [12]. In a review by Walker et al., 15 studies involving weight loss SMAs in adults and children were identified [34]. It was found that most SMA models were well accepted by patients, had low rates of attrition, and were very favorable models for weight management, especially among women and older patients. These studies highlight telemedicine SMA as a promising and cost‐effective way for the delivery of long‐term obesity management. In addition, SMAs are currently reimbursable by both commercial insurers and Medicare and are billed using standard evaluation and management (E/M) codes [35, 36]. There is also evidence that this model improves patient accessibility and provider financial productivity by allowing more patient encounters per hour, as compared to the traditional appointment model, while also being more educational and high‐yield to the patient due to the incorporation of pedagogic content and providing them with simultaneous access to multiple members of the care team [10, 35, 37, 38, 39]. Compared to this study, several other studies demonstrated a larger mean weight loss of about 6.8 kg, a higher percent weight loss from baseline between 5.3% and 6.4%, and a greater portion (56%–75%) of patients achieving 5% weight loss by 11–16 weeks of intervention [21, 22, 29, 30]. This is most likely related to those studies reporting data among patients in the initial weeks to months of weight management, while in this study, patients had already been enrolled in the program for an average of 18 months. It is widely known that weight loss trajectories demonstrate a plateau in weight loss between 3 and 12 months, as demonstrated in multiple studies, after an initial decline in weight [40, 41]. This could be due to declining compliance with diet and exercise consequent to decreasing motivation or other psychological factors, adaptive changes in metabolism, neurohormonal changes with lower leptin and PYY levels coupled with higher ghrelin and neuropeptide Y levels [42, 43, 44, 45]. This may also be related to several studies involving allied health care professionals like psychologists and exercise physiologists, which likely improved the efficacy of the intervention [29, 30]. Additionally, participants in this study were older than those in other studies, with an average age of 62 years compared to 42, 49 and 57 years [27, 29, 30]. Weight loss may be more challenging to achieve in older patients, given they tend to have less functional capacity and have more comorbidities limiting applicable lifestyle and pharmacologic interventions. When compared to the in‐person SMA cohort from the original study, the current results examining the telemedicine SMA cohort from the same program achieved comparable results [14]. While patients in the in‐person cohort lost 5.0% (5.1 kg), and 7.8% (8.4 kg) of their baseline weight after 6, and 12 months, respectively, mean weight loss among the telemedicine only cohort was 2.38% (2.38 ± 4.78 kg), and 4.55% (4.47 ± 7.77 kg) of their weight at 6 and 12 months, respectively. This is likely because the telemedicine cohort was in the chronic ongoing phase of their weight management, as opposed to the in‐person cohort, in early weight management. There are several compensatory neuro‐endocrine and metabolic attempts by the body to defend its weight set point after initial weight loss, and these pose difficulty in continued weight loss [45]. The success of the telemedicine cohort in achieving lower weights during the study period attests to the success of the program in not only initial weight loss but also continued weight management. The percentage weight changes were very similar, with ranges −29.2% to +10.7% in the in‐person cohort and −25.20% to +9.91% in the telemedicine cohort. Percent reductions in HgbA1c were similar between both cohorts with −3.1% and −3.2% changes respectively at 6 and 12 months in the first cohort and −2.19%, −3.70% in the second. The telemedicine only cohort demonstrated larger TG reductions with −33.6%, −41.14% changes as compared with −8.8% and 7.8%, respectively, at 6 and 12 months although the technique for analysis varied between both studies due to the use of logarithmic computation in this study. The hypothesis for a limited association between the number of classes attended and weight loss is that patient education is provided over multiple classes to cover topics including the roles of diet, exercise, sleep, stress management, and supplements in weight loss and maintenance. While attending more classes would place the patient at a more advantageous position in weight management, the largest yield topics are covered in the first four classes, contributing to decreased attendance in later classes and the decreasing yield of higher attendance in greater weight loss. In addition, since patients enroll at various times during the weight management journey, there may be variations in metabolic adaptation and compensatory behaviors that contribute to this finding. This study is distinct from previously published data in that the population is older with an average patient age of 62 years. Patients were tracked for 12 months, which is longer than most previous telemedicine SMA weight management programs. Additionally, changes in glycated hemoglobin as well as triglyceride levels were also measured, thus providing additional objective data regarding obesity related comorbidities and components of metabolic syndrome, validating the metabolic efficacy of this program. There are several limitations to this study. As a retrospective study with a relatively small group of self‐selected patients who were predominantly female, the results may not be generalizable to other populations. Self‐reported data regarding race and ethnicity were lacking. Changes in primary and secondary outcomes were only tracked for 12 months; thus, the longer‐term impact is unknown. It is important to study prolonged outcomes, as weight loss may plateau and even rebound over time [44]. In conclusion, this study demonstrates that telemedicine SMAs can be an efficient and effective approach to obesity management, in all stages. Author Contributions Keerthana Haridas: conceptualization, data curation, investigation, methodology, project administration, supervision, visualization, drafting all stages of the manuscript. Jeffrey Wei: conceptualization, data curation, investigation, methodology, resources, project administration, supervision, visualization, drafting all stages of the manuscript. Lei Lei: data curation, investigation, visualization, drafting all stages of the manuscript. Derek Pham: Formal analysis, methodology, software, validation, visualization, drafting all stages of the manuscript. Nicholas Jackson: formal analysis, methodology, software, validation, visualization, drafting all stages of the manuscript. Na Shen: conceptualization, data curation, investigation, methodology, resources, project administration, supervision, visualization, drafting all stages of the manuscript. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study.